A Phase 2 interventional study of Pasireotide LAR and Placebo in Somatostatin Analogs, Polycystic Liver Disease and Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-05-01.
Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment
Among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic — 4 open to participants now, 7 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Mayo Clinic.
Among the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, this one is the only one that started in 2012, is one of 2 in phase 2, and was the 4th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
This study's enrollment of 48 is close to the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Browse Polycystic Kidney, Autosomal Dominant studies →4 of the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic are open now, in 1 country. Each count lists the studies.
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2012.
Median enrollment 39 across the 6 interventional studies, 60 across the 9 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
7 of the studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05193981Mayo ClinicA Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD | 2026-12 |
| NCT04344769Mayo ClinicCharacterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 2026-12 |
| NCT05288998Mayo ClinicIntrarenal Microvasculature in ADPKD | 2026-12 |
| NCT04630613Mayo ClinicNOX4 and Related Biomarkers in ADPKD | 2026-12 |
| NCT07217158Mayo ClinicRole of ROS and cAMP-PKA Biomarkers in ADPKD | 2027-03-31 |
Among the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, from their registry updates:
Nothing recorded among them since 2026-09-25.
The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.
Pasireotide (SOM230) is a novel multi-receptor-targeted analog that has high affinity for four of the five SST receptor subtypes (SSTr1, SSTr2, SSTr3 and SSTr5); it has a 40-fold higher affinity and 158-fold higher functional activity for the SST5 receptor than octreotide. Because of its broad receptor binding profile, pasireotide may be more potent in Polycystic Liver Disease (PLD) than octreotide. In this randomized double blind placebo controlled trial the investigators will compare SOM230 treatment to placebo for 12 months in patients with PLD. The primary endpoints will be assessed at 12 months and patients receiving placebo then crossed over to SOM230, permitting all participants to receive SOM230 for the subsequent two years. Magnetic resonance imaging (MRI) will be used to assess liver volume - the primary endpoint, which will be assessed at baseline, end of years 1 and 3. This study will assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life over 12 months. (The investigators will not be assessing efficacy at 24 months.) The therapy way be effective in PLD but also may prove to be effective for many more patients with Polycystic Kidney Disease (PKD) which will be evaluated using eGFR and kidney volume using MRI.
The investigators plan to add other sub-sites in other locations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate bone marrow function:
No evidence of significant liver disease:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Pasireotide LAR
Drug: Pasireotide LAR
Drug: Placebo
Injectible, 60mg per month
To be injected once per month
Change in Liver Volume
Percent change was calculated for liver volumes using the equation=\[(12 month value-baseline value)/baseline value\]\*100\*12/12 month
Time frame: baseline , 12 month
Change in Kidney Volume
Percent change was calculated for kidney volumes using the equation=\[(12 month value-baseline value)/baseline value\]\*100\*12/12 month
Time frame: baseline to 12 months
Percentage Change in Estimated Glomerular Filtration Rate (eGFR)
eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. This value at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
Time frame: Baseline, 12 months
Percentage Change in Serum Creatinine
Serum creatinine level at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
Time frame: Baseline, 12 months
Percent Change in Blood Glucose
Blood glucose (mg/dLb) level at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
Time frame: Baseline, 12 months
Percentage Change in Hemoglobin A1C
Hemoglobin A1C level at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
Time frame: Baseline, 12 months
Percentage Change in Heart Rate
Heart rate, measured in beats per minute (BPM), at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
Time frame: Baseline, 12 months
Change in Quality of Life
Measured using the SF-36 health survey, which consist of eight subscales each scored on a range of 0 to 100 (0=worst imaginable, 100=best imaginable). Change calculated from baseline = 12 month value-baseline value
Time frame: Baseline, 12 months
| Milestone | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Started | 33 | 15 |
| Completed | 29 | 12 |
| Not completed | 4 | 3 |
Percent change was calculated for liver volumes using the equation=\[(12 month value-baseline value)/baseline value\]\*100\*12/12 month
| percentage of change | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Change in Liver Volume | -3.36 ± 7.33 | 6.29 ± 6.97 |
Percent change was calculated for kidney volumes using the equation=\[(12 month value-baseline value)/baseline value\]\*100\*12/12 month
| percentage of change | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Change in Kidney Volume | -1.37 ± 3.52 | 3.85 ± 4.49 |
eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. This value at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
| percentage of change | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Percentage Change in Estimated Glomerular Filtration Rate (eGFR) | -0.3 ± 14 | -2.2 ± 17.7 |
Serum creatinine level at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
| percentage of change | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Percentage Change in Serum Creatinine | 1.8 ± 12 | 3.4 ± 15.6 |
Blood glucose (mg/dLb) level at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
| percentage of change | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Percent Change in Blood Glucose | 39 ± 30 | 2.2 ± 15.2 |
Hemoglobin A1C level at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
| percentage of change | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Percentage Change in Hemoglobin A1C | 18 ± 11 | 1.6 ± 3.3 |
Heart rate, measured in beats per minute (BPM), at baseline and 12 months was used to calculate the percentage change by \[12 month value-baseline value)/baseline value\]\*100
| percentage of change | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Percentage Change in Heart Rate | -0.15 ± 0.2 | -0.1 ± 0.1 |
Measured using the SF-36 health survey, which consist of eight subscales each scored on a range of 0 to 100 (0=worst imaginable, 100=best imaginable). Change calculated from baseline = 12 month value-baseline value
| units on a scale | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Physical functioning | 4.7 ± 16 | -1 ± 8 |
| Physical role | 7.9 ± 36 | -3 ± 38 |
| Bodily pain | 5.5 ± 22 | 7 ± 12 |
| General health | -6.2 ± 14 | 2 ± 15 |
| Vitality | 4.5 ± 14 | -2 ± 17 |
| Social functioning | 0.0 ± 18 | -3 ± 8 |
| Role emotional | 0.0 ± 22 | 11 ± 5 |
| Mental health | 1.5 ± 12 | -1.8 ± 11 |
Collected over Adverse Events were collected from baseline to 12 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pasireotide LAR (SOM230) | 0/33 (0%) | 4/33 (12.1%) | 33/33 (100%) |
| Placebo Injection | 1/15 (6.7%) | 1/15 (6.7%) | 15/15 (100%) |
| Event | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| Abdominal hernia repairSurgical and medical procedures | 0/33 | 1/15 |
| Ruptured liver cystHepatobiliary disorders | 1/33 | 0/15 |
| Elevated alkaline phosphataseHepatobiliary disorders | 1/33 | 0/15 |
| Prolonged QT>480msecCardiac disorders | 1/33 | 0/15 |
| Right upper quadrant painGeneral disorders | 1/33 | 0/15 |
| Abdominal painGastrointestinal disorders | 1/33 | 0/15 |
| AscitesGeneral disorders | 1/33 | 0/15 |
| Event | Pasireotide LAR (SOM230) | Placebo Injection |
|---|---|---|
| HyperglycemiaMetabolism and nutrition disorders | 26/33 | 4/15 |
| DiabetesEndocrine disorders | 19/32 | 1/15 |
| DiarrheaGastrointestinal disorders | 17/33 | 8/15 |
| FatigueGeneral disorders | 13/33 | 3/15 |
| Pain abdomenGastrointestinal disorders | 11/33 | 1/15 |
| DizzinessNervous system disorders | 10/33 | 3/15 |
| BradycardiaCardiac disorders | 10/33 | 1/15 |
| NauseaGastrointestinal disorders | 9/33 | 3/15 |
| AlopeciaGeneral disorders | 9/33 | 0/15 |
| HeadacheNervous system disorders | 5/33 | 3/15 |
| Age, Continuous(years) | Pasireotide LAR (SOM230) | Placebo Injection | Total |
|---|---|---|---|
| Mean | 50.16 ± 8.63 | 51.40 ± 7.97 | 50.55 ± 8.37 |
| Sex: Female, Male(Participants) | Pasireotide LAR (SOM230) | Placebo Injection | Total |
|---|---|---|---|
| Female | 31 | 12 | 43 |
| Male | 2 | 3 | 5 |
| Race/Ethnicity, Customized(Participants) | Pasireotide LAR (SOM230) | Placebo Injection | Total |
|---|---|---|---|
| White | 29 | 15 | 44 |
| African American | 1 | 0 | 1 |
| Other | 3 | 0 | 3 |
| Region of Enrollment(participants) | Pasireotide LAR (SOM230) | Placebo Injection | Total |
|---|---|---|---|
| United States | 33 | 15 | 48 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2012 to primary completion in Sep 2018, 73 months.
Results were first posted in Mar 2020, 1 year 6 months after primary completion.
Of 17 phase 2 interventional studies under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's 73 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pasireotide
Polycystic Kidney, Autosomal Dominant →